Glenmark Pharma-led subsidiary receives USFDA approval for Ryaltris Nasal Spray

14 Jan 2022 , 10:59 AM

Glenmark Pharmaceuticals-led fully-owned subsidiary Glenmark Specialty S.A. (Switzerland), received USFDA approval on its New Drug Application (NDA)  for Ryaltris, an innovative, fixeddose (metered), prescription, combination drug product nasal spray for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients 12 years of age and older in the United States.

On Friday, Glenmark Pharma is currently trading at Rs515 down by Rs6.55 or 1.26% from its previous closing of Rs521.55 on the BSE.

“The FDA’s approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas.” said Robert Crockart Chief Commercial Officer of Glenmark Pharmaceuticals Limited. “With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms.”

Ryaltris will be marketed and distributed in the United States (US) by Hikma Specialty U.S.A., Inc., as part of its exclusive licensing agreement with Glenmark Specialty S.A (Switzerland).